Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

09:46 EST SpringWorks Therapeutics (SWTX) trading halted, volatility trading pause Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

DALLAS, Feb. 6, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by researchers at Penn State, could eliminate the need for refrigeration for ...

BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Roche Holding AG Akt-0.56% CHF240.64B ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...